Life Biociencias S/A Launches Desinfetantes Hospitalar LFE 250SX and LFE 200SX to Target Hospital Acquired Infections
SAN DIEGO, Feb. 19 /PRNewswire-FirstCall/ -- PURE Bioscience (Nasdaq: PURE) today announced that its distributor in Brazil, Life Biociencias S/A (Lifebio), recently obtained national regulatory approval for its silver dihydrogen citrate (SDC)-based hospital disinfectants, "Desinfetante Hospitalar LFE 200SX" and "Desinfetante Hospitalar LFE 250SX," which includes a virucidal claim, as published in the Brazilian Official Gazette No. 8.
L. Felippe C. De Castro, President and CEO of PCI commented, "Hospital acquired infections unfortunately plague patients worldwide, and the recent tragedy involving the death of a Brazilian model from a drug- resistant Pseudomonas aeruginosa infection has resulted in increased public awareness and scrutiny of this problem in our country. We are proud to present our hospital disinfectants featuring silver dihydrogen citrate (SDC) as the active ingredient as a powerful preventative technology to control hospital and community acquired infections."
Dr. Nilson Umberto Sacchelli Ribeiro, President of Lifebio and a Director of Grupo Nilson Ribeiro, added, "Receiving these registrations for hospital disinfectants, especially a virucidal product, demonstrates the Brazilian government's recognition of our product as a highly effective formulation. In addition to broad spectrum efficacy, our hospital disinfectants are odorless, non-corrosive and have been designated by the US EPA as a lowest-toxicity Category IV product. These characteristics elevate SDC above other disinfectant chemicals in Brazil and make it an ideal product for use in healthcare settings."
Michael L. Krall, President and CEO of PURE Bioscience stated, "With more than seven thousand hospitals in Brazil - approximately the same number as in the United States -- we look forward to a productive 2009 from Lifebio. We are pleased with the commitment of Lifebio and its pursuit of the necessary regulatory registrations to sell a wide variety of SDC-based products in Brazil. In addition to general and hospital disinfectants, Lifebio expects to receive regulatory approvals for other SDC-based products in the coming months."
In March 2007, PURE granted a license to market and sell its SDC-based products in Brazil to privately held Life Biociencias S/A of Apucarana, Parana in Brazil (Lifebio), a company of Grupo Nilson Ribeiro, together in a joint venture with privately held PCI International, Inc. of Lafayette, Louisiana (PCI). In July 2008, Life Biociencias S/A received Brazilian regulatory approval for its first SDC-based general disinfectant, "Desinfetante de Uso Geral LFE 100SX."
About Life Biociencias S/A
Lifebio, established solely to develop and promote silver dihydrogen citrate as a platform technology in Brazil, is a company of Grupo Nilson Ribeiro, also headquartered in Apucarana, Parana in Brazil. Lifebio purchases concentrate from PURE for blending, packaging and distribution of non-pharmaceutical SDC-based antimicrobial products. To that end, Lifebio/PCI has constructed a facility in Apucarana, Parana dedicated to blending and packaging SDC concentrate into end use disinfectant products.
About PURE Bioscience
PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
PURE Investor Contact: PURE Media Contact: Paul G. Henning, Vice President Suzanne Matick Cameron Associates Gutenberg Communications (212) 554-5462 (831) 479-1888 firstname.lastname@example.org Suzanne@gutenbergpr.com
|SOURCE PURE Bioscience|
Copyright©2009 PR Newswire.
All rights reserved